Minerva Neurosciences
NERV
19 hedge funds and large institutions have $2.75M invested in Minerva Neurosciences in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 8 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
5.6% less ownership
Funds ownership: 38% → 32.39% (-5.6%)
24% less funds holding
Funds holding: 25 → 19 (-6)
57% less call options, than puts
Call options by funds: $37K | Put options by funds: $87K
75% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 8
85% less capital invested
Capital invested by funds: $18.6M → $2.75M (-$15.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$131K |
| 2 |
Renaissance Technologies
New York
|
+$36.7K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.3K |
| 4 |
BlackRock
New York
|
+$3.22K |
| 5 |
Millennium Management
New York
|
+$1.39K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$2.31M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$261K |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$231K |
| 4 |
Truist Financial
Charlotte,
North Carolina
|
-$102K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$53K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$11K | -1,181 | Closed |
|
NERV Hedge Fund Activity: Q4 2022 in Review
19 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Minerva Neurosciences (NERV) for Q4 2022, worth a combined $2.75M — down 85% from $18.6M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of NERV and 2 opened new positions — a net loss of 6 holders — while 4 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Group, adding an estimated $131K. The largest seller was Artal Group, exiting entirely with an estimated $2.31M sold.
- 19 institutional investors held Minerva Neurosciences (NERV) as of Q4 2022, down from 25 in Q3 2022.
- Funds reported $2.75M of Minerva Neurosciences stock for Q4 2022, down 85% quarter-over-quarter.
- 2 funds opened new Minerva Neurosciences positions in Q4 2022 and 8 closed out, a net change of -6 holders.
- The largest Minerva Neurosciences buyer in Q4 2022 was Vanguard Group, an estimated $131K added.
- The largest Minerva Neurosciences seller in Q4 2022 was Artal Group, an estimated $2.31M sold.
Based on aggregated 13F filings for Q4 2022.